芬兰儿童SARS-CoV-2与1型糖尿病:一项观察性研究
该观察性队列研究利用芬兰儿科糖尿病登记数据,比较COVID-19大流行前18个月与三个大流行前对应时期儿童1型糖尿病发病率,发现大流行期间发病率显著升高(61.0 vs 52.3/10万人年,调整IRR 1.16),且新诊断患儿酮症酸中毒更常见、HbA1c更高、GAD抗体阳性更频繁,但仅0.9%检出SARS-CoV-2抗体。
要点
- 大流行期间儿童1型糖尿病发病率较参考期显著升高,调整IRR为1.16(95%CI 1.06-1.25;p=0.0006)。
- 大流行期间新诊断患儿更常出现糖尿病酮症酸中毒、HbA1c更高、GAD抗体阳性更频繁(均p<0.001)。
- 仅0.9%受检新诊断患儿检出感染诱导的SARS-CoV-2抗体,发病率升高可能源于封锁和物理 distancing 而非 SARS-CoV-2 感染直接效应。
核心结论
- 大流行期间诊断的儿童和青少年1型糖尿病病情更重。
- 观察到的1型糖尿病发病率升高可能源于封锁和物理 distancing 而非 SARS-CoV-2 感染的直接效应。
研究设计与样本
- 观察性队列研究,使用芬兰儿科糖尿病登记数据。
- 纳入15岁以下儿童,比较COVID-19大流行前18个月(2020年3月1日至2021年8月31日)与三个大流行前对应18个月时期(2014年3月1日至2015年8月31日;2016年3月1日至2017年8月31日;2018年3月1日至2019年8月31日)的1型糖尿病发病率。
- 排除确诊单基因糖尿病的儿童;比较两个队列的表型和HLA基因型,并分析新诊断1型糖尿病患者SARS-CoV-2抗体阳性比例。
主要发现
- 大流行期间诊断785例儿童和青少年1型糖尿病,参考期诊断2096例。
- 大流行期间15岁以下儿童1型糖尿病发病率为61.0/10万人年(95%CI 56.8-65.4),参考期为52.3/10万人年(95%CI 50.1-54.6)。
- 大流行期间与参考期相比,年龄和性别调整的发病率比为1.16(95%CI 1.06-1.25;p=0.0006)。
- 大流行期间诊断的儿童更常出现糖尿病酮症酸中毒(p<0.001)、HbA1c更高(p<0.001)、诊断时谷氨酸脱羧酶抗体阳性更频繁(p<0.001)。
- 两个时期HLA基因型分布无显著差异;大流行期间诊断者中仅583例受检者中的5例(0.9%)检出感染诱导的SARS-CoV-2抗体阳性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Some epidemiological studies have suggested an increase in incidence of type 1 diabetes during the COVID-19 pandemic, however the mechanism(s) behind such an increase have yet to be identified. In this study we aimed to evaluate the possible role of the SARS-CoV-2 virus in the reported increase in the rate of type 1 diabetes. METHODS: In this observational cohort study using data from the Finnish Pediatric Diabetes Register (FPDR), we assessed the incidence of type 1 diabetes (number of children with newly diagnosed type 1 diabetes per 100 000 person-years during the pandemic and the reference period) during the first 18 months of the COVID-19 pandemic in children in Finland younger than 15 years old compared with a reference period which included three corresponding pre-pandemic periods also obtained from the FPDR. Children with confirmed monogenic diabetes were excluded. We also compared the phenotype and HLA genotype of the disease between these two cohorts, and analysed the proportion of newly diagnosed people with type 1 diabetes testing positive for SARS-CoV-2 antibodies. FINDINGS: 785 children and adolescents in Finland were diagnosed with type 1 diabetes from March 1, 2020, to Aug 31, 2021. In the reference period, which comprised three similar 18-month terms (from March 1, 2014, to Aug 31, 2015; March 1, 2016, to Aug 31, 2017; and March 1, 2018, to Aug 31, 2019) 2096 children and adolescents were diagnosed. The incidence of type 1 diabetes was 61·0 per 100 000 person-years (95% CI 56·8-65·4) among children younger than 15 years old during the pandemic, which was significantly higher than during the reference period (52·3 per 100 000 person-years; 50·1-54·6). The incidence rate ratio adjusted for age and sex for the COVID-19 pandemic was 1·16 (1·06-1·25; p=0·0006) when compared with the reference period. The children diagnosed during the COVID-19 pandemic had more often diabetic ketoacidosis (p<0·001), had a higher HbA1c (p<0·001), and tested more frequently positive for glutamic acid debarboxylase antibodies at diagnosis (p<0·001) than those diagnosed before the pandemic. There were no significant differences in the distribution of HLA genotypes between the two periods. Only five of those diagnosed during the pandemic (0·9%) of 583 tested positive for infection-induced SARS-CoV-2 antibodies. INTERPRETATION: Children and adolescents diagnosed with type 1 diabetes during the pandemic had a more severe disease at diagnosis. The observed increase in type 1 diabetes incidence during the first 18 months could be a consequence of lockdown and physical distancing rather than a direct effect of SARS-CoV-2 infection. FUNDING: Helsinki University Hospital Research Funds, EU Horizon 2020 (Versatile emerging infectious disease observatory project), Academy of Finland, Sigrid Jusélius Foundation, Jane & Aatos Erkko Foundation, and Medicinska understödsföreningen Liv och Hälsa. TRANSLATIONS: For the Finnish and Swedish translations of the abstract see Supplementary Materials section.
引用
- Knip M, Parviainen A, Turtinen M, et al. SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study. Lancet Diabetes Endocrinol. 2023. PMID: 36958868. doi:10.1016/S2213-8587(23)00041-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。